One of the biggest gambles in biotech history is about to be tested on Wall Street.
Moderna, the high-flying yet secretive developer of messenger RNA therapeutics, filed papers on Friday afternoon outlining its long-awaited IPO. In its prospectus, Moderna set an initial target of $500 million for the offering, which would make it the largest biotech IPO in history. That figure is subject to change as the company gets closer to its debut.
Moderna will trade on the Nasdaq under the symbol “MRNA,” should it complete the offering.
Moderna’s IPO has been anticipated for years. Formed in 2010 by Flagship Pioneering,… Read more »
UNDERWRITERS AND PARTNERS